Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity
Authors' conclusion
Most adults and paediatric patients with obesity had suboptimal adherence to GLP-1 RA use over 12 months.
Study context
- Population
- Individuals aged ≥10 years with obesity without diabetes who initiated GLP-1 RAs, MarketScan commercial claims 2021–2023
- Participants
- 201,229 vs 1,139
- Exposure
- Adults vs Paediatric
- Adultsn = 201,229
- Paediatricn = 1,139
- Outcome
- GLP-1 RA adherence trajectories (monthly proportion of days covered)
- Follow-up
- 12 months
Methodological detailsclaims database (MarketScan commercial, 2021-2023), group-based trajectory modelling
- Claims database (MarketScan commercial, 2021-2023)
- Group-based trajectory modelling
Main finding
As reported in the abstract
12-month adherence trajectories
- Adults: immediate discontinuers
- 19.6%
- Adults: early discontinuers
- 23.5%
- Adults: late discontinuers
- 20.7%
- Adults: intermittent adherents
- 5.5%
- Adults: persistent users
- 30.7%
- Adults: mean annual proportion of days covered (PDC) range across trajectories
- 0.10 to 0.87
- Paediatric: each trajectory group approximately
- 18%-22%
- Paediatric: persistent users
- 20.3%
Observational data: associations, not effects.
Further findings
| Outcome | OR |
|---|---|
| Factors associated with persistent use: Northeast vs South regionAdults: Northeast vs Adults: South · multivariable logistic regression | 1.32 |
| Factors associated with persistent use: Northeast vs South regionPaediatric: Northeast vs Paediatric: South · multivariable logistic regression | 1.65 |
Original publication
Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity. Diabetes Obes Metab. Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →